HOME >> BIOLOGY >> NEWS
Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial

SAN DIEGO, Calif., November 16, 2005 -- Results from a Phase 2 rheumatoid arthritis (RA) study assessing the safety and efficacy of golimumab (CNTO 148), a fully-human anti-TNF-alpha therapy, showed that it achieved the primary endpoint of the study. In this dose-ranging trial, more than 60 percent of patients with moderately to severely active RA treated with golimumab and methotrexate (MTX) experienced at least 20 percent improvement in arthritis symptoms at week 16. Additionally, one-quarter of patients receiving golimumab and MTX achieved remission as evaluated by Disease Activity Score 28 (DAS28). These findings will be presented this week at the American College of Rheumatology 2005 Annual Scientific Meeting.

"When treating a debilitating disease like RA, it is important to have several treatment options, and we are encouraged by the safety and efficacy data we have seen thus far for golimumab," said Jonathan Kay, MD, Director, Clinical Trials, Rheumatology Unit, Massachusetts General Hospital, Associate Clinical Professor of Medicine, Harvard University School of Medicine and lead study investigator.

Golimumab, developed by Centocor, Inc. and Schering-Plough, is a fully-human anti-TNF-alpha IgG1 monoclonal antibody that targets and neutralizes both the soluble and the membrane-bound form of TNF-alpha. Golimumab is currently being investigated for administration by either subcutaneous (SC) injection or intravenous (IV) infusion.

Data from the study showed that significantly more patients in all groups receiving SC injections of golimumab plus MTX achieved ACR 50 response (marked improvement in arthritis symptoms according to the American College of Rheumatology scoring criteria) versus patients receiving placebo plus MTX. Adults with active RA for at least three months' duration despite MTX therapy were randomized to one of five treatment groups: placebo every two weeks or golimumab 50 or 100 mg every two weeks or every four wee
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
16-Nov-2005


Page: 1 2 3 4

Related biology news :

1. ASBMB Schering-Plough Award lecture to focus on histone modifications in transcription
2. Cardiac patches stimulate regeneration, improve function after heart attack
3. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
4. Critical protein prevents DNA damage from persisting through generations
5. Early environmental exposure may accelerate age-related neurodegeneration
6. First demonstration of new hair follicle generation in an animal model
7. Enhanced environment restores memory in mice with neurodegeneration
8. Liver regeneration may be simpler than previously thought
9. Invasive grass may impede forest regeneration
10. Research project tackles regeneration gap
11. Whole body regeneration from a blood vessel

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
(Date:3/13/2017)... Germany , March 13, 2017 Future of security: ... ... DERMALOGs Face Matching enables to match face ... forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... April 25, 2017 , ... Franz ... Lisp (CL) development tools, and market leader for Semantic Graph Database ... now available within the most effective system for developing and deploying applications to ...
(Date:4/25/2017)... PROVIDENCE, R.I. , April 25, 2017 /PRNewswire/ ... EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology ... in autoimmune disease and allergy. Tregitopes, ... discovered in human immunoglobulin by EpiVax CEO ... Martin. Similar to intravenous immunoglobulin G, an autoimmune ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Partners.     , Covalent’s Analytical Services unit provides high-quality data to clients, ... within 24 hours of receipt. There are no price premiums, and customers are ...
(Date:4/24/2017)... ... April 24, 2017 , ... It is well established that ... the broad application of this cellular target engagement concept to drug discovery has ... thermal stabilization assays are valuable methods for particular applications, but they can require ...
Breaking Biology Technology:
Cached News: